Core Insights - Medtronic reported its strongest revenue growth in 10 quarters, achieving 8.7% reported growth and 6.0% organic growth for Q3 fiscal 2026, surpassing Wall Street expectations with revenue of $9.02 billion and non-GAAP EPS of $1.36 [1] Revenue Performance - The Cardiovascular Portfolio led the growth with 13.8% reported growth, driven by an 80% increase in Cardiac Ablation Solutions [1] - U.S. cardiac ablation revenue surged 137%, primarily due to the pulsed field ablation portfolio [1] - Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes segment posted 8.3% organic growth to $796 million [1] Regulatory and M&A Developments - Medtronic achieved significant regulatory milestones, including CE Mark approval for Sphere-360 and FDA clearance for the Hugo robotic-assisted surgery system, with initial cases completed in February 2026 [1] - The company also secured FDA clearance for the Stealth AXiS spinal system and made strategic acquisitions, including CathWorks and an investment in Anteris [1] Profitability and Future Outlook - Non-GAAP operating profit was $2.18 billion with a 24.1% margin, although GAAP net income declined 11.67% year-over-year to $1.14 billion [1] - Management reiterated full-year guidance for approximately 5.5% organic growth and EPS of $5.62 to $5.66, which includes a $185 million tariff impact [1]

Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]